360 related articles for article (PubMed ID: 35859731)
1. Functionalized Mesoporous Silica Nanoparticles for Drug-Delivery to Multidrug-Resistant Cancer Cells.
Igaz N; Bélteky P; Kovács D; Papp C; Rónavári A; Szabó D; Gácser A; Kónya Z; Kiricsi M
Int J Nanomedicine; 2022; 17():3079-3096. PubMed ID: 35859731
[TBL] [Abstract][Full Text] [Related]
2. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
3. Increasing the cytotoxicity of doxorubicin in breast cancer MCF-7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery system.
Wang X; Teng Z; Wang H; Wang C; Liu Y; Tang Y; Wu J; Sun J; Wang H; Wang J; Lu G
Int J Clin Exp Pathol; 2014; 7(4):1337-47. PubMed ID: 24817930
[TBL] [Abstract][Full Text] [Related]
4. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
Zhang X; Li F; Guo S; Chen X; Wang X; Li J; Gan Y
Biomaterials; 2014 Apr; 35(11):3650-65. PubMed ID: 24462359
[TBL] [Abstract][Full Text] [Related]
5. Controlled synthesis and size effects of multifunctional mesoporous silica nanosystem for precise cancer therapy.
Ma B; He L; You Y; Mo J; Chen T
Drug Deliv; 2018 Nov; 25(1):293-306. PubMed ID: 29334793
[TBL] [Abstract][Full Text] [Related]
6. Macroporous silica nanoparticles for delivering Bcl2-function converting peptide to treat multidrug resistant-cancer cells.
Xu W; Ge P; Niu B; Zhang X; Liu J; Xie J
J Colloid Interface Sci; 2018 Oct; 527():141-150. PubMed ID: 29787950
[TBL] [Abstract][Full Text] [Related]
7. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance.
Huang IP; Sun SP; Cheng SH; Lee CH; Wu CY; Yang CS; Lo LW; Lai YK
Mol Cancer Ther; 2011 May; 10(5):761-9. PubMed ID: 21411714
[TBL] [Abstract][Full Text] [Related]
8. Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles.
Pan L; Liu J; He Q; Wang L; Shi J
Biomaterials; 2013 Apr; 34(11):2719-30. PubMed ID: 23337327
[TBL] [Abstract][Full Text] [Related]
9. Co-Delivery of Silymarin and Metformin Dual-Loaded in Mesoporous Silica Nanoparticles Synergistically Sensitizes Breast Cancer Cell Line to Mitoxantrone Chemotherapy.
Rezaei Harandi Z; Heidari R; Reiisi S
IEEE Trans Nanobioscience; 2023 Oct; 22(4):872-880. PubMed ID: 37022888
[TBL] [Abstract][Full Text] [Related]
10. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
Shen J; He Q; Gao Y; Shi J; Li Y
Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
[TBL] [Abstract][Full Text] [Related]
11. Dendrimer-like mesoporous silica nanospheres with suitable surface functionality to combat the multidrug resistance.
Xu W; Gao X; Ge P; Jiang F; Zhang X; Xie J
Int J Pharm; 2018 Dec; 553(1-2):349-362. PubMed ID: 30393166
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer.
Slapak EJ; El Mandili M; Brink MST; Kros A; Bijlsma MF; Spek CA
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445886
[TBL] [Abstract][Full Text] [Related]
13. A Sequentially Responsive Nanosystem Breaches Cascaded Bio-barriers and Suppresses P-Glycoprotein Function for Reversing Cancer Drug Resistance.
Liu J; Zhao L; Shi L; Yuan Y; Fu D; Ye Z; Li Q; Deng Y; Liu X; Lv Q; Cheng Y; Xu Y; Jiang X; Wang G; Wang L; Wang Z
ACS Appl Mater Interfaces; 2020 Dec; 12(49):54343-54355. PubMed ID: 32959645
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Polydopamine-Coated Mesoporous Silica Nanorods and Spheres for the Delivery of Hydrophilic and Hydrophobic Anticancer Drugs.
Pada AK; Desai D; Sun K; Prakirth Govardhanam N; Törnquist K; Zhang J; Rosenholm JM
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336697
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of mitomycin C-loaded and LDL-conjugated mesoporous silica nanoparticles for inhibiting the proliferation of pterygium subconjunctival fibroblasts.
Wu M; Wang S; Wang Y; Zhang F; Shao T
Exp Eye Res; 2020 Aug; 197():108124. PubMed ID: 32598971
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery and controlled release of doxorubicin to cancer cells by smart ATP-responsive Y-shaped DNA structure-capped mesoporous silica nanoparticles.
Bagheri E; Alibolandi M; Abnous K; Taghdisi SM; Ramezani M
J Mater Chem B; 2021 Feb; 9(5):1351-1363. PubMed ID: 33447840
[TBL] [Abstract][Full Text] [Related]
17. siRNA delivery using intelligent chitosan-capped mesoporous silica nanoparticles for overcoming multidrug resistance in malignant carcinoma cells.
Heidari R; Khosravian P; Mirzaei SA; Elahian F
Sci Rep; 2021 Oct; 11(1):20531. PubMed ID: 34654836
[TBL] [Abstract][Full Text] [Related]
18. Polyaspartic acid-anchored mesoporous silica nanoparticles for pH-responsive doxorubicin release.
Hakeem A; Zahid F; Zhan G; Yi P; Yang H; Gan L; Yang X
Int J Nanomedicine; 2018; 13():1029-1040. PubMed ID: 29497295
[TBL] [Abstract][Full Text] [Related]
19. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals.
Lu J; Liong M; Li Z; Zink JI; Tamanoi F
Small; 2010 Aug; 6(16):1794-805. PubMed ID: 20623530
[TBL] [Abstract][Full Text] [Related]
20. Chitosan-capped mesoporous silica nanoparticles as pH-responsive nanocarriers for controlled drug release.
Hu X; Wang Y; Peng B
Chem Asian J; 2014 Jan; 9(1):319-27. PubMed ID: 24115568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
